CoChat
Sign Up
Cited by 255Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes Management and Education

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Mathieu, Chantal, Dandona, Paresh, Gillard, Pieter, Senior, Peter, Hasslacher, Christoph, Araki, Eiichi, Lind, Marcus, Bain, Stephen C., Jabbour, Serge, Arya, Niki, Hansen, Lars, Thorén, Fredrik, Langkilde, Anna Maria, DEPICT-2 Investigators, Luquez, Cecilia, Manghi, Federico Perez, Ulla, Maria Rosa, Moisello, Maria Alejandra, Visco, Virginia, De Lapertoza, Silvia Gorban, Solis, Silvana Ernestina, Farias, Javier, Sposetti, Georgina, Gillard, Pieter, Abrams, Pascale, van Ypersele de Strihou, Marina, Conway, James, Pedersen, Sue, Senior, Peter, Liutkus, Joanne F., Yip, Churn-Ern, Punthakee, Zubin, Bernier, Frederic, Lochnan, Heather, Woo, Vincent, Elliott, Thomas, Palma, Juan, Merino, Carmen Solis, Vargas, Alfredo Danin, Wendisch, Ulrich, Reichel, Andreas, Seufert, Jochen, Becker, Bernd, Alawi, Hasan, Birkenfeld, Andreas L., Hasslacher, Christoph, Luedemann, Joerg, Schaum, Thomas, Marck, Cornelia, Sauter, Joachim, Aigner, Ulrich, Onishi, Yukiko, Seino, Hiroaki, Sato, Yuichi, Nunoi, Kiyohide, Yamauchi, Akira, Nakashima, Eitaro, Ikeda, Hiroki, Shiraiwa, Toshihiko, Yamasaki, Yoshimitsu, Yokoyama, Hiroki, Nakamura, Kunihiko, Noritake, Masayuki, Miyauchi, Shozo, Hakoda, Tomomi, Hirohata, Yoshihide, Hasegawa, Atsushi, Fukumoto, Yoshihide, Nagashima, Hirotaka, Takihata, Masahiro, Kamada, Tetsuro, Jinnouchi, Hideaki, Ono, Yuri, Watanabe, Takayuki, Ohashi, Hiroshi, Takai, Masahiko, Seguchi, Tadashi, Yamazaki, Katsuya, Maeda, Hajime, Iwasaki, Shingo, De Valk, H.W., Kooy, Adriaan, Landewe-Cleuren, Sabine, Madziarska, Katarzyna, Stankiewicz, Andrzej, Wasilewska, Katarzyna, Rudofsky, Gottfried, Malecki, Maciej, Pankowska, Ewa, Szyprowska, Ewa, Lukaszewicz, Monika, Tokarska, Lidia, Bondar, Irina, Karpova, Irina, Ruyatkina, Ludmila, Zalevskaya, Alsu, Sardinov, Ruslan, Khalimov, Yury, Sjoberg, Folke, Koskinen, Pekka, Curiac, Dan, Lind, Marcus, Bach-Kliegel, Birgit, Schultes, Bernd, Issa, Basil G., Kilvert, Anne, Pereira, Olivia, Bain, Stephen, Mishra, Biswa, Bhatnagar, Deepak, Chuck, Leonard, Gorson, David, Robertson, David, Casaubon, Luis, Chaykin, Louis, Frias, Juan Pablo, Hsia, Stanley, Jenders, Robert, Lerman, Sam, Segel, Scott, Weissman, Peter, Chang, Anna, Reed, John, Madu, Ivy-Joan, Bressler, Peter, Abbott, Lisa, Gangi, Sumana, Wheeler, Kate, Cohen, Kenneth, Biggs, William, Jabbour, Serge, Karounos, Dennis, Menon, Sajeev, Miers, Wendell, Aleppo, Grazia, Lefebvre, Gigi, Sugimoto, Danny, Ferraro, Robert, Kelly, Richard, Twahirwa, Marcel, Case, Christopher, Klonoff, David, Denker, Paul, Hollander, Priscilla, Welch, Michelle, Leinung, Matthew, Kotek, Larry, McGill, Janet, Shlesinger, Yshay, Huffman, Cynthia, Aronoff, Stephen, Lorber, Daniel, Terrelonge, Antonio, Akhrass, Firas, Bredefeld, Cindy, Hershon, Kenneth, Lenhard, James, Donovan, Daniel, Stonesifer, Larry, Greenberg, Craig, Ipp, Eli, Bhargava, Anuj, Bao, Shichun·2018·Diabetes Care
DOI 10.2337/dc18-0623
Open this paper in CoChat — free account

Abstract

Objective This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; ClinicalTrials.gov, NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct therapy to adjustable insulin in patients with inadequately controlled type 1 diabetes (HbA 1c 7.5-10.5%). Research design and methods Patients were randomized 1:1:1 to dapagliflozin 5 mg ( n = 271), dapagliflozin 10 mg ( n = 270), or placebo ( n = 272) plus insulin. Insulin dose was adjusted by investigators according to self-monitored glucose readings, local guidance, and individual circumstances. Results Baseline characteristics were balanced between treatment groups. At week 24, dapagliflozin significantly decreased HbA 1c (primary outcome; difference vs. placebo: dapagliflozin 5 mg -0.37% [95% CI -0.49, -0.26], dapagliflozin 10 mg -0.42% [-0.53, -0.30]), total daily insulin dose (-10.78% [-13.73, -7.72] and -11.08% [-14.04, -8.02], respectively), and body weight (-3.21% [-3.96, -2.45] and -3.74% [-4.49, -2.99], respectively) ( P 70 to ≤180 mg/dL) versus placebo were significantly improved. More patients receiving dapagliflozin achieved a reduction in HbA 1c ≥0.5% without severe hypoglycemia compared with placebo. Adverse events were reported for 72.7%, 67.0%, and 63.2% of patients receiving dapagliflozin 5 mg, dapagliflozin 10 mg, and placebo, respectively. Hypoglycemia, including severe hypoglycemia, was balanced between groups. There were more adjudicated definite diabetic ketoacidosis (DKA) events with dap…

Overview

Integrity signals

Registry

Crossref · 10.2337/dc18-0623

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 23 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., Hansen, L., Thorén, F., Langkilde, A. M., DEPICT-2 Investigators, Luquez, C., Manghi, F. P., Ulla, M. R., Moisello, M. A., Visco, V., De Lapertoza, S. G., Solis, S. E., Farias, J., Sposetti, G., Gillard, P., Abrams, P., van Ypersele de Strihou, M., Conway, J., Pedersen, S., Senior, P., Liutkus, J. F., Yip, C.-E., Punthakee, Z., Bernier, F., Lochnan, H., Woo, V., Elliott, T., Palma, J., Merino, C. S., Vargas, A. D., Wendisch, U., Reichel, A., Seufert, J., Becker, B., Alawi, H., Birkenfeld, A. L., Hasslacher, C., Luedemann, J., Schaum, T., Marck, C., Sauter, J., Aigner, U., Onishi, Y., Seino, H., Sato, Y., Nunoi, K., Yamauchi, A., Nakashima, E., Ikeda, H., Shiraiwa, T., Yamasaki, Y., Yokoyama, H., Nakamura, K., Noritake, M., Miyauchi, S., Hakoda, T., Hirohata, Y., Hasegawa, A., Fukumoto, Y., Nagashima, H., Takihata, M., Kamada, T., Jinnouchi, H., Ono, Y., Watanabe, T., Ohashi, H., Takai, M., Seguchi, T., Yamazaki, K., Maeda, H., Iwasaki, S., De Valk, H. W., Kooy, A., Landewe-Cleuren, S., Madziarska, K., Stankiewicz, A., Wasilewska, K., Rudofsky, G., Malecki, M., Pankowska, E., Szyprowska, E., Lukaszewicz, M., Tokarska, L., Bondar, I., Karpova, I., Ruyatkina, L., Zalevskaya, A., Sardinov, R., Khalimov, Y., Sjoberg, F., Koskinen, P., Curiac, D., Lind, M., Bach-Kliegel, B., Schultes, B., Issa, B. G., Kilvert, A., Pereira, O., Bain, S., Mishra, B., Bhatnagar, D., Chuck, L., Gorson, D., Robertson, D., Casaubon, L., Chaykin, L., Frias, J. P., Hsia, S., Jenders, R., Lerman, S., Segel, S., Weissman, P., Chang, A., Reed, J., Madu, I.-J., Bressler, P., Abbott, L., Gangi, S., Wheeler, K., Cohen, K., Biggs, W., Jabbour, S., Karounos, D., Menon, S., Miers, W., Aleppo, G., Lefebvre, G., Sugimoto, D., Ferraro, R., Kelly, R., Twahirwa, M., Case, C., Klonoff, D., Denker, P., Hollander, P., Welch, M., Leinung, M., Kotek, L., McGill, J., Shlesinger, Y., Huffman, C., Aronoff, S., Lorber, D., Terrelonge, A., Akhrass, F., Bredefeld, C., Hershon, K., Lenhard, J., Donovan, D., Stonesifer, L., Greenberg, C., Ipp, E., Bhargava, A., & Bao, S.
Affiliations
  • KU Leuven (BE)
  • University at Buffalo, State University of New York (US)
  • Kumamoto University (JP)
  • Diabetes Research Unit, Swansea University, Swansea, Wales, U.K.
  • AstraZeneca (United States) (US)
  • MedImmune, Gaithersburg, MD
  • AstraZeneca, Gothenburg, Sweden
  • AstraZeneca (Sweden) (SE)
  • University of Alberta (CA)
  • Diabetesinstitut Heidelberg (DE)
  • NU Hospital Group (SE)
  • Swansea University (GB)
  • Thomas Jefferson University (US)
Corresponding author
Mathieu, Chantal
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2018-07-19
Volume
41
Issue
9
Pages
1938-1946
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc18-0623
OpenAlex
W2884380775
Cited by
252
References
23
Citations by year
2026: 10 · 2025: 27 · 2024: 19 · 2023: 25 · 2022: 25 · 2021: 27 · 2020: 52 · 2019: 55 · 2018: 11
FWCI
29.05
Type
journal article
Language
en
Open access
closed
Licence
www.diabetesjournals.org/content/license (vor, 34 d)
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • AstraZeneca
  • Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
dapagliflozin, type 1 diabetes, inadequate glycemic control, SGLT2 inhibitors, insulin dose reduction, HbA1c reduction, weight loss, hypoglycemia, adverse events, glycemic variability, drug safety and efficacy
MeSH terms
Adult, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Diabetic Ketoacidosis, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review